Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $715.0 million.

  • Arrowhead Pharmaceuticals' Short-term Investments rose 4327.34% to $715.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $715.0 million, marking a year-over-year increase of 4327.34%. This contributed to the annual value of $692.8 million for FY2025, which is 1980.75% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Short-term Investments stood at $715.0 million, which was up 4327.34% from $692.8 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Short-term Investments' 5-year high stood at $911.7 million during Q1 2025, with a 5-year trough of $125.8 million in Q1 2021.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Short-term Investments value was $322.8 million (recorded in 2022), while the average stood at $381.0 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Short-term Investments crashed by 4589.45% in 2023 and then soared by 20786.3% in 2024.
  • Arrowhead Pharmaceuticals' Short-term Investments (Quarter) stood at $126.0 million in 2021, then surged by 137.76% to $299.6 million in 2022, then tumbled by 45.89% to $162.1 million in 2023, then surged by 207.86% to $499.0 million in 2024, then skyrocketed by 43.27% to $715.0 million in 2025.
  • Its last three reported values are $715.0 million in Q4 2025, $692.8 million for Q3 2025, and $770.6 million during Q2 2025.